The only difference detected in tumor-infiltrating lymphocytes with respect to negative controls in the uninjected lesion was an increase in the proliferation of CD8+ T cells in those mice treated with IL-12, IL-12-(αCTLxαCSF1R), and IL-12-(αCTLxαPD-L1) (Figures S6B and S6C). The gene discussed is CD8A; the disease is neoplasm.